Windlas Biotech Ltd
Windlas Biotech Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Windlas Biotech Ltd's next results in your feed
Guidance rank: #81 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Windlas Biotech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Net Revenue from Operations: Rs. 264 Cr, a 19% YoY increase from Rs. 222 Cr in Q2 FY26 (Page 13). Q2FY27 EBITDA: Rs. 29 Cr (Reported), Rs. 36 Cr (excluding non-cash ESOP expenses).
From Windlas Biotech Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Windlas Biotech's revenue grow in the September 2026 quarter?
- Q2 FY27 Net Revenue from Operations: Rs. 264 Cr, a 19% YoY increase from Rs. 222 Cr in Q2 FY26 (Page 13).
- H1 FY27 Net Revenue: Rs. 512 Cr, an 18% YoY increase from Rs. 432 Cr in H1 FY26 (Page 13).
- Vertical-wise Q2 FY27 revenue growth:
- Generic Formulations CDMO: Rs. 160 Cr in Q2 FY27, 34% growth YoY (Page 10).
- Trade Generics & Institutional: Rs. 36 Cr in Q2 FY27, 13% contribution (Page 10).
- Exports: Rs. 12 Cr in Q2 FY27, 26% growth YoY (Page 10).
2 more points from Windlas Biotech Ltd's call on revenue
Create a free account to keep reading this call
What happened to Windlas Biotech's margins in Q2 FY27?
See what Windlas Biotech Ltd said on profitability & margins — free account, 30 seconds.
What capex is Windlas Biotech planning?
- Plant-6: Commercialized in September 2026, significant addition to manufacturing infrastructure (Page 8, 25, 34).
- Capex for FY26: Rs. 73 Cr invested (Page 25).
- Capital Work in Progress (CWIP): Rs. 56 Cr as of Mar-26, indicating ongoing projects (Page 33).
- Plant-4 & Plant-5: Received EU GMP certification in Q2FY27; injectables facility progressing steadily (Pages 7, 8).
- P-2 extension and injectables facility: Investments continuing steadily (Page 8).
- FY26 reported capex includes full plant 6; excluding Plant-6 CWIP in ROCE/ROE calculations (Pages 8, 31).
2 more points from Windlas Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Windlas Biotech raising money or cutting debt?
See what Windlas Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Windlas Biotech's order book?
See what Windlas Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Windlas Biotech Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.
Windlas Biotech Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 264 |
| Operating profit (EBITDA) | 29 |
| Operating margin | 11.1% |
| Profit before tax | 23 |
| Net profit (PAT) | 18 |
| EPS (₹) | 8.75 |
Source: Windlas Biotech Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹248 Cr, net profit ₹18 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Windlas Biotech's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Symbiotec Pharma (Q2 FY27)
280 Cr, up 43% YoY from Rs. Key investor presentation takeaways from Symbiotec Pharmalab Ltd's Q2 FY27 investor presentation — and how it ranks against sector p
- Hester Bios (Q2 FY27)
Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). Key results statement takeaways from Hester Biosciences Ltd's Q
- Glenmark Pharmaceuticals (Q2 FY27)
42,473 million, down 29.8% YoY. Key investor presentation takeaways from Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation — and how it ranks against
- Rubicon Research Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10). Key investor presentation takeaways
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Windlas Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Windlas Biotech Ltd Q2 FY27 results?
Q2 FY27 Net Revenue from Operations: Rs. 264 Cr, a 19% YoY increase from Rs. 222 Cr in Q2 FY26 (Page 13). Q2FY27 EBITDA: Rs. 29 Cr (Reported), Rs. 36 Cr (excluding non-cash ESOP expenses).
What is Windlas Biotech Ltd share price analysis?
Windlas Biotech Ltd currently shows a neutral. The stock trades at a P/E of 27.1 with a market cap of ₹1,802 Cr. Investors should review the full earnings analysis for detailed insights.
Is Windlas Biotech Ltd planning capital expenditure?
Plant-6: Commercialized in September 2026, significant addition to manufacturing infrastructure (Page 8, 25, 34).
Keep Windlas Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.